Actavis Llc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ACTAVIS LLC, and what generic and branded alternatives to ACTAVIS LLC drugs are available?
ACTAVIS LLC has twelve approved drugs.
There are two tentative approvals on ACTAVIS LLC drugs.
Summary for Actavis Llc
| US Patents: | 0 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 12 |
| Patent Litigation for Actavis Llc: | See patent lawsuits for Actavis Llc |
| PTAB Cases with Actavis Llc as petitioner: | See PTAB cases with Actavis Llc as petitioner |
Drugs and US Patents for Actavis Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Llc | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 208216-001 | Apr 29, 2016 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Actavis Llc | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 204880-001 | Mar 5, 2018 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Actavis Llc | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 203551-003 | Apr 12, 2013 | RX | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Actavis Llc | PEMETREXED | pemetrexed | SOLUTION;INTRAVENOUS | 208419-003 | Aug 21, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
